Literature DB >> 30403183

UNBS5162 inhibits colon cancer growth via suppression of PI3K/Akt signaling pathway.

Fan Zhang1, Hui-Zeng Lv2, Ji-Ming Liu2, Xiao-Yong Ye2, Cun-Chuan Wang1.   

Abstract

Colon cancer is a common cause of cancer-related death worldwide. However, the underlying mechanism of tumor progression of colon cancer remains far from being elucidated. In the present study, we report the role of UNBS5162 in colon cancer. UNBS5162 is a naphthalimide that can intercalate into DNA and suppress the expression level of CXCL chemokines. Here, we investigated its effect on cell proliferation, mobility and apoptosis in HCT116 cells, and explored the underlying mechanism. A CCK8 assay revealed that UNBS5162 can block the proliferation of colon cancer cells. Base on a Transwell assay, we showed that cell migration and invasion ability of HCT116 cells are inhibited by UNBS5162. In addition, Annexin V-FITC/PI assay and Western blot analysis were performed to detect whether UNBS5162 could induce cell apoptosis. The results indicated that UNBS5162 increases the number of apoptotic cells remarkably. Furthermore, Western blot analysis demonstrated that UNBS5162 down-regulates the expression level of Bcl2, and up-regulates that of Bax as well as the level of activated Caspase-3. Moreover, we examined the impact of UNBS5162 on PI3K/Akt signaling pathway. UNBS5162 substantially inhibited the phosphorylation of Akt and its downstream effector mTOR, and reduced the expression of p-70. Taken together, these results suggest that UNBS5162 should be considered as a potent therapeutic anticancer agent that targets the PI3K/AKT signaling pathway.
© 2018 médecine/sciences – Inserm.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30403183     DOI: 10.1051/medsci/201834f117

Source DB:  PubMed          Journal:  Med Sci (Paris)        ISSN: 0767-0974            Impact factor:   0.818


  1 in total

1.  Protosappanin B Exerts Anti-tumor Effects on Colon Cancer Cells via Inhibiting GOLPH3 Expression.

Authors:  Xue-Cong Zheng; Ze-Sheng Shi; Cheng-Zhi Qiu; Zhong-Shi Hong; Chun-Xiao Wang; Hai-Bin Zhuang; Zhi-Chuan Chen; Jian-Peng Pan
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.